Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. (MBRX) announced that the Mexican Patent Office granted Patent No. 436849 for its lung-targeted liposomal Annamycin technology; the patent remains in force until November 23, 2040.
To date in September 2026, Moleculin issued 888,400 common shares through its at-the-market offering for $0.48 million in aggregate gross proceeds. Following completion of those issuances, the company will have 20,385,780 shares outstanding. The Series I Warrants’ exercise price was reduced from $0.75 to $0.51 per share after the ATM share issuances; the warrants cover up to 37,130,001 shares. Moleculin said it will require significant additional financing, for which it has no commitments, to conduct the clinical trials described.
Moleculin Biotech, Inc. (MBRX) reports that on September 15, 2026 it received a Nasdaq staff determination letter stating that the company is not in compliance with the $1.00 minimum bid price requirement, because its common stock’s closing bid price was below $1.00 for 30 consecutive business days from July 31, 2026 through September 11, 2026. Due to a prior 1-for-25 reverse stock split effected on December 1, 2025, Nasdaq Listing Rule 5810(c)(3)(A)(iv) makes the company ineligible for the usual 180‑day compliance period. Moleculin plans to request a hearing before the Nasdaq Hearings Panel; a timely request will stay any suspension or delisting, and the stock will continue trading on The Nasdaq Capital Market during the hearing process, though there is no assurance continued listing will be granted.
Moleculin Biotech, Inc. (MBRX) reported that new preclinical and translational data on its lead drug candidate Annamycin (naxtarubicin) will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
The presentations examine how Annamycin’s lipophilic structure drives tissue-specific concentration, its activity as a topoisomerase II–targeting anthracycline, and preclinical antitumor effects in pancreatic cancer that may involve CD8+ T cell cytotoxicity. These data are intended to inform development of Annamycin alongside the ongoing MIRACLE pivotal Phase 2/3 trial in relapsed or refractory acute myeloid leukemia.
Moleculin Biotech, Inc. (MBRX) reported that on August 31, 2026 it is using a corporate presentation for its investor communications, which is included as Exhibit 99.1. The presentation is furnished under a disclosure item for informational purposes and is not deemed filed or incorporated into other securities law filings unless specifically stated.
Moleculin Biotech, Inc. (MBRX) is the subject of a Schedule 13D filing by its Executive Vice President and Chief Financial Officer, Jonathan P. Foster, who reports beneficial ownership of 1,288,207 shares of common stock, representing 6.3% of the company’s outstanding shares.
The position consists of 305,673 shares held directly, 879,999 shares underlying Series I Common Stock Purchase Warrants, and 102,535 shares underlying options and other warrants exercisable within 60 days of August 19, 2026. Foster acquired 293,333 shares and the Series I warrants in an August 3, 2026 public offering at a combined price of $0.75 per share plus three warrants, for about $219,999.75, using personal funds. The warrants are exercisable at $0.75 per share until August 3, 2031, include a beneficial ownership limitation (increased by election from 4.99% to 9.99% effective October 18, 2026), an anti-dilution provision with a floor price of $0.21, and a right to receive the Black Scholes Value in certain fundamental transactions.
Moleculin Biotech, Inc. (MBRX) received a Schedule 13D from its Chairman, Chief Executive Officer and President, Walter V. Klemp, and his holding company AnnaMed, Inc., reporting significant ownership in the company’s common stock.
As of this filing, Mr. Klemp may be deemed to beneficially own 2,070,761 shares of common stock of Moleculin, representing 9.87% of the 19,477,380 shares outstanding as of August 6, 2026. This position includes 564,976 shares of common stock (564,340 held directly and 636 held through AnnaMed), 1,250,959 shares underlying currently exercisable Series I Common Stock Purchase Warrants, and 254,826 shares underlying options and other warrants exercisable within 60 days of August 19, 2026.
On August 3, 2026, Mr. Klemp invested personal funds in a public offering, purchasing 533,333 shares and Series I warrants to purchase up to 1,599,999 shares at a combined price of $0.75 per share plus three warrants, for an aggregate of about $399,999.75. The warrants are exercisable at $0.75 per share until August 3, 2031, subject to a beneficial ownership limitation that Mr. Klemp elected to increase from 4.99% to 9.99% effective October 18, 2026, and include anti-dilution and Black Scholes-based provisions in certain transactions.
Moleculin Biotech, Inc. (MBRX) is asking stockholders to vote at the October 9, 2026 in‑person annual meeting in Houston. Proposals include electing five directors, ratifying the independent auditor, and a non‑binding advisory vote to approve executive compensation.
Stockholders are also asked to approve an amendment to the 2024 Equity Incentive Plan to increase shares authorized, an amendment to the Amended and Restated Certificate of Incorporation to eliminate supermajority voting requirements for future charter amendments, and an amendment granting the Board authority, in its sole discretion, to implement a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑20 prior to the one‑year anniversary of the meeting. Another proposal would authorize adjournment of the meeting to solicit additional proxies if needed.
Record date was August 19, 2026, with 19,477,380 common shares outstanding, each entitled to one vote. The proxy describes governance structure, committee independence, detailed director and executive biographies, significant equity‑based compensation, and ownership, including the CEO’s 9.87% and a 9.9% institutional holder subject to warrant beneficial ownership limits.
Moleculin Biotech, Inc. (MBRX) is increasing the capacity of its existing at-the-market common stock program under its At The Market Offering Agreement with Roth Capital Partners to allow sales of up to $19,700,000 of common stock from and after August 21, 2026, not including shares previously sold. This supplements earlier ATM capacities of $6,500,000 set in July 2025 and $8,200,000 set in December 2025. As of this supplement, Moleculin has sold 486,775 shares for aggregate gross sales of $1,890,241 under the ATM program. The company’s common stock trades on the Nasdaq Capital Market under the symbol MBRX, with a last reported sale price of $0.5906 per share on August 20, 2026. Public float is approximately $64,852,256 based on 19,477,380 outstanding shares, of which 1,311,482 are held by affiliates, and Moleculin states it is subject to the one‑third public float limit for primary offerings under General Instruction I.B.6 of Form S‑3.
Moleculin Biotech, Inc. plans to hold its 2026 annual stockholder meeting on October 9, 2026 at its Houston headquarters, with 19,477,380 common shares entitled to vote as of August 19, 2026. Stockholders will vote on electing five directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase shares authorized for issuance.
Additional proposals include an advisory vote on executive compensation, eliminating supermajority voting requirements to amend the certificate of incorporation, authorizing the board to implement a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑20 within one year, and potentially adjourning the meeting to solicit more proxies. The proxy details board composition and independence, committee structures, executive and director pay, ownership (directors and officers as a group hold 12.69% of outstanding shares), and equity plans, including performance-based restricted stock units that vest upon specified corporate milestones.
Moleculin Biotech reported second quarter 2026 results and updated progress on its pivotal Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory acute myeloid leukemia. Preliminary unblinded data from the first 45 patients in Part A showed complete remission rates at least three times greater than the control arm, with no evidence of cardiotoxicity reported to date. Enrollment is on track to reach 90 patients in September 2026, with an unblinded efficacy readout expected in the December 2026 to February 2027 timeframe and Part B initiation planned for the first half of 2027.
Research and development expenses for the quarter were $5.5 million, up from $3.6 million a year earlier, mainly driven by the MIRACLE trial. General and administrative expenses were approximately $2.1 million, flat year over year. The company reported a quarterly net loss of $7.6 million, or $1.40 per share. Cash and cash equivalents were $7.3 million as of June 30, 2026, and together with $9.3 million raised after quarter-end, management expects this to fund planned operations into the first quarter of 2027, while also noting that significant additional financing will be required to conduct clinical trials as described.